Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Assets (2016 - 2025)

United Therapeutics' Assets history spans 17 years, with the latest figure at $7.9 billion for Q4 2025.

  • For Q4 2025, Assets rose 7.01% year-over-year to $7.9 billion; the TTM value through Dec 2025 reached $7.9 billion, up 7.01%, while the annual FY2025 figure was $7.9 billion, 7.01% up from the prior year.
  • Assets for Q4 2025 was $7.9 billion at United Therapeutics, up from $7.4 billion in the prior quarter.
  • Across five years, Assets topped out at $7.9 billion in Q2 2025 and bottomed at $4.6 billion in Q1 2021.
  • The 5-year median for Assets is $6.6 billion (2023), against an average of $6.4 billion.
  • The largest annual shift saw Assets rose 21.48% in 2023 before it grew 0.63% in 2024.
  • A 5-year view of Assets shows it stood at $5.2 billion in 2021, then rose by 16.94% to $6.0 billion in 2022, then increased by 18.57% to $7.2 billion in 2023, then increased by 2.75% to $7.4 billion in 2024, then increased by 7.01% to $7.9 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Assets are $7.9 billion (Q4 2025), $7.4 billion (Q3 2025), and $7.9 billion (Q2 2025).